Osteo-Site Vertebral Balloon and Complex VCF Treatment Toolbox Launches

Osteo-Site Vertebral Balloon for vertebral augmentation has launched. The news was announced today by IZI Medical Products, a manufacturer of interventional radiology devices.

Osteo-Site Vertebral Balloon completes IZI’s offering of Vertebral Compression Fracture (“VCF”) treatment options, which include Osteo-Site Vertebroplasty, Osteo-Site Balloon Kyphoplasty, Blazer Curved Needle Augmentation, and Kiva PEEK Implant-based augmentation.

“We want to enable our physicians to choose the most clinically appropriate solution for their patients when treating vertebral compression fractures,” said Greg Groenke, CEO, IZI Medical. “We have created an integrated portfolio of VCF treatment devices with the ability to switch between different treatment options with ease.”

“IZI has completed the VCF toolbox: Kiva for metastatic VCF’s, Blazer Curved Needle for targeted cement deployment in sclerotic bone and blastic metastases, and now Osteo-site Balloon and curved needle for osteoporotic fractures. IZI has made it simple to switch between all of them which gives me intra-operative flexibility,” said Dr. Kieran Murphy, Professor of Radiology at University Health Network Toronto.

The new Osteo-site Vertebral Balloon is designed to create a cavity within the vertebral body. Currently, the balloon is available in 10G and 11G sizes. “The Osteo-site balloon will be paired with our Duro-Ject Injector, which provides maximum control and feedback during injection and minimizes radiation exposure with a long flexible tubing,” said Jovie Soriano, SVP Marketing and Business Development, IZI Medical. “We have also made improvements to our Murphy access needles based on physician feedback that will be included in the Osteo-Site Balloon kit.”

IZI Medical’s VCF portfolio will be supported by a dedicated sales team of direct representatives and independent distributors to drive market penetration in the United States, followed by expansion into Europe.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version